AI Could Help Speed Up the Search for Better Health Treatments. That Could Be Good News for Humanity, and the Anthropic IPO.

Barchart
Barchart에서 열기
AI Could Help Speed Up the Search for Better Health Treatments. That Could Be Good News for Humanity, and the Anthropic IPO.

Could we see an end to severe health and mental issues over the next decade? According to Anthropic (ANT) CEO Dario Amodei, it’s possible, thanks to artificial intelligence. In fact, as quoted by Seeking Alpha, he said, “If today we look at things like cancer, Alzheimer's, heart disease, mental illness, these will be relics of the past in, I think, less than a decade.”

That's quite the claim about the power of AI to forever change the face of medicine. And it’s easy to see why it got attention. For anyone who has watched a loved one go through treatment, even a few years of faster progress in their overall medical or mental health would matter immensely.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

Where AI Could Help Speed Up Research

Presently, Anthropic is testing how AI can help at several points in drug development. In October, it described work with companies including BigHat Biosciences, Generate Biomedicines (GENB), Divergence Labs, and Bristol Myers Squibb (BMY). The projects range from improving experimental drug candidates to planning early clinical studies. 

As noted by Anthropic's website:

BigHat Biosciences worked with Claude to improve two antibody fragments that could become parts of future medicines. One was designed to recognize cancer cells. The other could help a medicine stay in the body longer. Generate Biomedicines used Claude Code to help rework a component of CAR T-cell therapy. The approach already treats some blood cancers, and the team is exploring whether changes could make it more effective against solid tumors. Bristol Myers Squibb wants to see whether Claude can help scientists find new leads in decades of company research. The drugmaker plans to test whether the tool can sift through those records and help researchers decide which potential drug targets are worth pursuing. Divergence Labs is studying whether it can interrupt an allergic reaction to food before it starts. Its approach aims to pull IgE, the antibody that helps trigger the reaction, off the immune cells it clings to. Claude helped the team come up with about 35,000 potential antibody designs in a month.

Finding a Drug Is Only the Beginning

Imagine a research team trying to decide which of thousands of possible compounds to test first. AI can help rank the candidates, giving researchers a smaller list to take into the lab. That could save time at a stage where scientists often have more ideas than they have the resources to pursue. Then, researchers need to find out which doses people can tolerate, whether benefits last, and whether side effects emerge as more people take a drug. An AI model can help researchers choose what to test next. However, some of the most important answers still come from following patients over time.

Or, look at mental health issues. Consider two people diagnosed with depression. One may struggle to sleep, while the other can barely get out of bed. They may also respond differently to the same treatment. AI could help researchers search for patterns in who responds to a particular therapy or medication. If those patterns hold up in real clinics, they could help patients spend less time trying treatments that bring little relief. 

Ten years from now, the numbers worth checking will be how many people avoided a late-stage cancer diagnosis, how many lived longer after treatment, and how many got lasting relief from depression. If AI helps move those numbers in the right direction, it will have changed medicine in ways patients can feel.

Anthropic will start trading on the Nasdaq under the ticker symbol ANT on Thursday, Nov. 19, 2026. 


On the date of publication, Ian Cooper did not directly have a position in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

I Used This Options Strategy to Profit from the Post-IPO Plunge in SpaceX. Now I’ll Use It Again on ANT Stock After Anthropic Starts Trading. Alphabet Stock Is Falling. Here’s Why Investors Should Be Buying the Dip. Dear Nvidia Stock Fans, Mark Your Calendars for December 1 Ahead of Intuit Earnings, Here's What Barchart Data Says Comes Next for INTU Stock